{"id":"terbutaline","rwe":[],"_fda":{"id":"9f8ee6b8-61e1-478a-90de-57358fdb5905","set_id":"0a95bc4f-34d3-4b5e-841b-6839e1c1e0c7","openfda":{"upc":["0371205939304","0371205938307"],"unii":["576PU70Y8E"],"route":["ORAL"],"rxcui":["857677","857683"],"spl_id":["9f8ee6b8-61e1-478a-90de-57358fdb5905"],"brand_name":["Terbutaline Sulfate"],"spl_set_id":["0a95bc4f-34d3-4b5e-841b-6839e1c1e0c7"],"package_ndc":["71205-938-30","71205-938-60","71205-938-90","71205-938-00","71205-938-55","71205-939-30","71205-939-60","71205-939-90","71205-939-00","71205-939-55"],"product_ndc":["71205-938","71205-939"],"generic_name":["TERBUTALINE SULFATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["TERBUTALINE SULFATE"],"manufacturer_name":["Proficient Rx LP"],"application_number":["ANDA211832"],"original_packager_product_ndc":["24979-132","24979-133"]},"version":"2","warnings":["WARNINGS Deterioration of Asthma Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of terbutaline sulfate than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. Use of Anti-Inflammatory Agents The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids. Cardiovascular Effects Terbutaline sulfate, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of terbutaline sulfate at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, terbutaline sulfate, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Seizures There have been rare reports of seizures in patients receiving terbutaline; seizures did not recur in these patients after the drug was discontinued."],"pregnancy":["Pregnancy Teratogenic Effects Pregnancy Category C There are no adequate and well-controlled studies of terbutaline sulfate in pregnant women. Published animal studies show that rat offspring exhibit alterations in behavior and brain development, including decreased cellular proliferation and differentiation when dams were treated subcutaneously with terbutaline during the late stage of pregnancy and lactation period. Terbutaline exposures in rat dams were approximately 6.5 times the common human dose in adults of 15 mg/day, on a mg/m 2 basis. Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [See Boxed Warning: Tocolysis and Contraindications, Tocolysis . ] In animal embryofetal developmental studies, no teratogenic effects were observed in offspring when pregnant rats and rabbits received terbutaline sulfate at oral doses up to 50 mg/kg/day, approximately 32 and 65 times, respectively, the maximum recommended daily oral dose for adults, on a mg/m 2 basis. Terbutaline sulfate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"overdosage":["OVERDOSAGE The median subcutaneous lethal dose of terbutaline sulfate in mature rats is approximately 165 mg/kg (approximately 90 times the maximum recommended daily oral dose for adults on a mg/m 2 basis). The median subcutaneous lethal dose of terbutaline sulfate in young rats is approximately 2000 mg/kg (approximately 1100 times the maximum recommended daily oral dose for adults on a mg/m 2 basis). The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS , e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Hypokalemia may also occur. There is no specific antidote. Treatment consists of discontinuation of terbutaline sulfate together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of terbutaline sulfate. In the alert patient who has taken excessive oral medication, the stomach should be emptied by induced emesis followed by lavage. In the unconscious patient, the airway should be secured with a cuffed endotracheal tube before lavage, and emesis should not be induced. Instillation of activated charcoal slurry may help reduce absorption of terbutaline. Adequate respiratory exchange should be maintained, and cardiac and respiratory support provided as needed. The patient should be monitored until signs and symptoms of overdosage have subsided."],"description":["DESCRIPTION Terbutaline sulfate USP is a beta-adrenergic agonist bronchodilator available as tablets of 2.5 mg (2.05 mg of the free base) and 5 mg (4.1 mg of the free base) for oral administration. Terbutaline sulfate is ±-α-[( tert –butylamino) methyl]-3,5-dihydroxybenzyl alcohol sulfate (2:1) (salt). The molecular formula is (C 12 H 19 NO 3 ) 2 • H 2 SO 4 and the structural formula is Terbutaline sulfate USP is a white to gray-white crystalline powder. It is odorless or has a faint odor of acetic acid. It is soluble in water and in 0.1N hydrochloric acid, slightly soluble in methanol, and insoluble in chloroform. Its molecular weight is 548.65. Inactive Ingredients: lactose monohydrate, pregelatinized starch, microcrystalline cellulose, povidone, and magnesium stearate. image description"],"precautions":["PRECAUTIONS General Terbutaline, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, including ischemic heart disease, hypertension, and cardiac arrhythmias; hyperthyroidism; diabetes mellitus; hypersensitivity to sympathomimetic amines; and convulsive disorders. Significant changes in systolic and diastolic blood pressure have been seen and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator. Immediate hypersensitivity reactions and exacerbation of bronchospasm have been reported after terbutaline administration. Beta-adrenergic agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation. Large doses of intravenous terbutaline sulfate have been reported to aggravate preexisting diabetes and ketoacidosis. Information for Patients The action of terbutaline sulfate should last up to 6 hours or longer. Terbutaline sulfate should not be used more frequently than recommended. Do not increase the dose or frequency of terbutaline sulfate without consulting your physician. If you find that treatment with terbutaline sulfate becomes less effective for symptomatic relief, your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. While taking terbutaline sulfate, other inhaled drugs and asthma medications should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, tremor or nervousness. If you are pregnant or nursing, contact your physician about use of terbutaline sulfate. Effective and safe use of terbutaline sulfate includes an understanding of the way that it should be administered. Drug Interactions The concomitant use of terbutaline sulfate with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. However, this does not preclude the use of an aerosol bronchodilator of the adrenergic-stimulant type for the relief of an acute bronchospasm in patients receiving chronic oral therapy with terbutaline sulfate. Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. Beta-Blockers Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as terbutaline sulfate, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics. Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year study in Sprague-Dawley rats, terbutaline sulfate caused a significant and dose-related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 50 mg/kg, and above (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m 2 basis). In a 21-month study in CD-1 mice, terbutaline sulfate showed no evidence of tumorigenicity at dietary doses up to 200 mg/kg (approximately 55 times the maximum recommended daily oral dose for adults on a mg/m 2 basis). The mutagenicity potential of terbutaline sulfate has not been determined. Reproduction studies in rats using terbutaline sulfate demonstrated no impairment of fertility at oral doses up to 50 mg/kg (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m 2 basis). Pregnancy Teratogenic Effects Pregnancy Category C There are no adequate and well-controlled studies of terbutaline sulfate in pregnant women. Published animal studies show that rat offspring exhibit alterations in behavior and brain development, including decreased cellular proliferation and differentiation when dams were treated subcutaneously with terbutaline during the late stage of pregnancy and lactation period. Terbutaline exposures in rat dams were approximately 6.5 times the common human dose in adults of 15 mg/day, on a mg/m 2 basis. Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [See Boxed Warning: Tocolysis and Contraindications, Tocolysis . ] In animal embryofetal developmental studies, no teratogenic effects were observed in offspring when pregnant rats and rabbits received terbutaline sulfate at oral doses up to 50 mg/kg/day, approximately 32 and 65 times, respectively, the maximum recommended daily oral dose for adults, on a mg/m 2 basis. Terbutaline sulfate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Use in Labor and Delivery Because of the potential for beta-agonist interference with uterine contractility, use of terbutaline sulfate for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk. Terbutaline crosses the placenta. After single dose IV administration of terbutaline to 22 women in late pregnancy who were delivered by elective Cesarean section due to clinical reasons, umbilical blood levels of terbutaline were found to range from 11% to 48% of the maternal blood levels. Nursing Mothers It is not known whether this drug is excreted in human milk. Therefore, terbutaline sulfate should be used during nursing only if the potential benefit justifies the possible risk to the newborn. Pediatric Use Terbutaline sulfate is not recommended for patients under the age of 12 years because of insufficient clinical data to establish safety and effectiveness (see DOSAGE AND ADMINISTRATION ). Geriatric Use Clinical studies of terbutaline sulfate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED Terbutaline sulfate tablets, USP are packaged in bottles of 100 and 1000 tablets. Descriptions of the 2.5 and 5 mg tablets follow: Tablets 2.5 mg - White to off-white, oval tablets, scored on one side and engraved with “T132” on the other side Bottles of 30 NDC 71205-938-30 Bottles of 60 NDC 71205-938-60 Bottles of 90 NDC 71205-938-90 Bottles of 100 NDC 71205-938-00 Bottles of 500 NDC 71205-938-55 Tablets 5 mg - White to off-white, round, scored and engraved “T” above and “133” below the score on the scored side. Bottles of 30 NDC 71205-939-30 Bottles of 60 NDC 71205-939-60 Bottles of 90 NDC 71205-939-90 Bottles of 100 NDC 71205-939-00 Bottles of 500 NDC 71205-939-55 Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure Manufactured for: TWi Pharmaceuticals USA, Inc. Paramus, NJ 07652 Manufactured by: TWi Pharmaceuticals, Inc. Taoyuan City, 32063, Taiwan Rev. 07/19 Repackaged and Relabeled by: Proficient Rx LP Thousand Oaks, CA 91320 image description"],"boxed_warning":["WARNING: TOCOLYSIS Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [see Contraindications, Tocolysis . ]"],"geriatric_use":["Geriatric Use Clinical studies of terbutaline sulfate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["Pediatric Use Terbutaline sulfate is not recommended for patients under the age of 12 years because of insufficient clinical data to establish safety and effectiveness (see DOSAGE AND ADMINISTRATION )."],"effective_time":"20220401","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Therefore, terbutaline sulfate should be used during nursing only if the potential benefit justifies the possible risk to the newborn."],"pharmacokinetics":["Pharmacokinetics Oral administration of 5-mg terbutaline sulfate tablets or 5 mg terbutaline sulfate in solution in 17 healthy, adult, male subjects, resulted in mean (SD) peak plasma terbutaline concentration of 8.3 (3.9) and 8.6 (3.6) ng/mL, which were observed at median (range) times of 2 (1 to 3) and 1.5 (0.5 to 3.0) hours after dosing. The mean (SD) AUC (0-48) values were 54.6 (26.8) and 53.1 (23.5) hr•ng/mL, and corresponded to a bioavailability of 103% for the tablet relative to the solution. After oral administration of terbutaline, 51 to 62 mcg/kg of body weight, to 3 healthy male subjects, peak serum levels of 3.1 to 6.2 ng/mL were observed 1 to 3 hours later. In the same study, after 3 days only 30% to 50% of the dose was recovered from urine and the remainder from the feces, which may indicate poor absorption. After an oral dose to asthmatic patients, the elimination half-life of terbutaline was approximately 3.4 hours. In comparison to oral dosing, subcutaneous administration of 0.5 mg of terbutaline sulfate to 17 healthy, adult, male subjects resulted in a mean (SD) peak plasma terbutaline concentration of 9.6 (3.6) ng/mL, which was observed at a median (range) time of 0.5 (0.08 to 1.0) hours after dosing. The mean (SD) AUC (0-48) and total body clearance values were 29.4 (14.2) hr•ng/mL, and 311 (112) mL/min, respectively. The terminal half-life was determined in 9 of the 17 subjects and had a mean (SD) of 5.7 (2.0) hours. About 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug. The sulfate conjugate is a major metabolite of terbutaline, and urinary excretion is the primary route of elimination. There are no reports of any clinical pharmacokinetic studies investigating dose proportionality, effect of food, or special population studies with terbutaline."],"adverse_reactions":["ADVERSE REACTIONS Adverse reactions observed with terbutaline sulfate are similar to those commonly seen with other sympathomimetic amines. All of these reactions are generally transient in nature and usually do not require treatment. The frequency of these side effects appears to diminish with continued therapy. The following table lists the adverse reactions seen in 199 patients treated with terbutaline sulfate tablets during six double-blind crossover studies and four double-blind parallel studies (short- and long-term) performed in the United States. Percent Incidence of Adverse Reactions (Total Daily Dosage Range 5 to 15 mg) Terbutaline N=199 Reaction % Nervous System Nervousness 35.0 Tremor 15.0 Somnolence 5.5 Dizziness 3.5 Anxiety 1.0 Insomnia 1.5 Cardiovascular Palpitations 5.0 Tachycardia 3.5 Extrasystoles ventricular 1.5 Vasodilations 1.0 Digestive Nausea 3.0 Dry mouth 1.5 Body as a Whole Headache 7.5 Asthenia 2.0 Skin and Appendages Sweating 1.0 The following adverse effects each occurred in fewer than 1% of patients: hallucinations, rash, paresthesia, hypertonia, (muscle cramps), vomiting. There have been rare reports of elevations in liver enzymes and of hypersensitivity vasculitis."],"contraindications":["CONTRAINDICATIONS 1. Tocolysis Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. [see Boxed Warning: Tocolysis . ] 2. Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product."],"drug_interactions":["Drug Interactions The concomitant use of terbutaline sulfate with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. However, this does not preclude the use of an aerosol bronchodilator of the adrenergic-stimulant type for the relief of an acute bronchospasm in patients receiving chronic oral therapy with terbutaline sulfate."],"labor_and_delivery":["Use in Labor and Delivery Because of the potential for beta-agonist interference with uterine contractility, use of terbutaline sulfate for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk. Terbutaline crosses the placenta. After single dose IV administration of terbutaline to 22 women in late pregnancy who were delivered by elective Cesarean section due to clinical reasons, umbilical blood levels of terbutaline were found to range from 11% to 48% of the maternal blood levels."],"general_precautions":["General Terbutaline, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, including ischemic heart disease, hypertension, and cardiac arrhythmias; hyperthyroidism; diabetes mellitus; hypersensitivity to sympathomimetic amines; and convulsive disorders. Significant changes in systolic and diastolic blood pressure have been seen and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator. Immediate hypersensitivity reactions and exacerbation of bronchospasm have been reported after terbutaline administration. Beta-adrenergic agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation. Large doses of intravenous terbutaline sulfate have been reported to aggravate preexisting diabetes and ketoacidosis."],"teratogenic_effects":["Teratogenic Effects Pregnancy Category C There are no adequate and well-controlled studies of terbutaline sulfate in pregnant women. Published animal studies show that rat offspring exhibit alterations in behavior and brain development, including decreased cellular proliferation and differentiation when dams were treated subcutaneously with terbutaline during the late stage of pregnancy and lactation period. Terbutaline exposures in rat dams were approximately 6.5 times the common human dose in adults of 15 mg/day, on a mg/m 2 basis. Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [See Boxed Warning: Tocolysis and Contraindications, Tocolysis . ] In animal embryofetal developmental studies, no teratogenic effects were observed in offspring when pregnant rats and rabbits received terbutaline sulfate at oral doses up to 50 mg/kg/day, approximately 32 and 65 times, respectively, the maximum recommended daily oral dose for adults, on a mg/m 2 basis. Terbutaline sulfate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY In vitro and in vivo pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta 2 -adrenergic receptors. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta 2 -receptors in the human heart, existing in a concentration between 10% to 50%. The precise function of these receptors has not been established (see WARNINGS ). In controlled clinical studies in patients given terbutaline sulfate orally, proportionally greater changes occurred in pulmonary function parameters than in heart rate or blood pressure. While this suggests a relative preference for the beta 2 -receptors in man, the usual cardiovascular effects commonly associated with other sympathomimetic agents were also observed with terbutaline sulfate. The pharmacologic effects of beta-adrenergic agonists, including terbutaline, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic 3’, 5’-adenosine monophosphate (cAMP). Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Controlled clinical studies have shown that terbutaline sulfate relieves bronchospasm in chronic obstructive pulmonary disease by significantly increasing pulmonary function (e.g., an increase of 15% or more in FEV 1 and in FEF 25%-75% ). After administration of terbutaline sulfate tablets, a measurable change in flow rate usually occurs within 30 minutes, and a clinically significant improvement in pulmonary function occurs within 60 to 120 minutes. The maximum effect usually occurs within 120 to 180 minutes. Terbutaline sulfate also produces a clinically significant decrease in airway and pulmonary resistance, which persists for 4 hours or longer. Significant bronchodilator action (as measured by airway resistance, FEF 25%-75% or PEFR) has also been demonstrated for up to 8 hours in some studies. In studies comparing the effectiveness of terbutaline sulfate with that of ephedrine for up to 3 months, both drugs maintained a significant improvement in pulmonary function throughout this period of treatment. Preclinical Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines were administered concurrently. The clinical significance of these findings is unknown. Pharmacokinetics Oral administration of 5-mg terbutaline sulfate tablets or 5 mg terbutaline sulfate in solution in 17 healthy, adult, male subjects, resulted in mean (SD) peak plasma terbutaline concentration of 8.3 (3.9) and 8.6 (3.6) ng/mL, which were observed at median (range) times of 2 (1 to 3) and 1.5 (0.5 to 3.0) hours after dosing. The mean (SD) AUC (0-48) values were 54.6 (26.8) and 53.1 (23.5) hr•ng/mL, and corresponded to a bioavailability of 103% for the tablet relative to the solution. After oral administration of terbutaline, 51 to 62 mcg/kg of body weight, to 3 healthy male subjects, peak serum levels of 3.1 to 6.2 ng/mL were observed 1 to 3 hours later. In the same study, after 3 days only 30% to 50% of the dose was recovered from urine and the remainder from the feces, which may indicate poor absorption. After an oral dose to asthmatic patients, the elimination half-life of terbutaline was approximately 3.4 hours. In comparison to oral dosing, subcutaneous administration of 0.5 mg of terbutaline sulfate to 17 healthy, adult, male subjects resulted in a mean (SD) peak plasma terbutaline concentration of 9.6 (3.6) ng/mL, which was observed at a median (range) time of 0.5 (0.08 to 1.0) hours after dosing. The mean (SD) AUC (0-48) and total body clearance values were 29.4 (14.2) hr•ng/mL, and 311 (112) mL/min, respectively. The terminal half-life was determined in 9 of the 17 subjects and had a mean (SD) of 5.7 (2.0) hours. About 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug. The sulfate conjugate is a major metabolite of terbutaline, and urinary excretion is the primary route of elimination. There are no reports of any clinical pharmacokinetic studies investigating dose proportionality, effect of food, or special population studies with terbutaline."],"indications_and_usage":["INDICATIONS AND USAGE Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema."],"adverse_reactions_table":["<table ID=\"_RefID0EDKAE\" width=\"100%\"><caption>Percent Incidence of Adverse Reactions (Total Daily Dosage Range 5 to 15 mg) Terbutaline N=199</caption><col width=\"49%\"/><col width=\"49%\"/><thead><tr><th align=\"left\" styleCode=\"Botrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Reaction</content></th><th align=\"left\" styleCode=\"Botrule Toprule \" valign=\"top\"><content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td colspan=\"2\" styleCode=\"Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Nervous System</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph> Nervousness</paragraph></td><td valign=\"top\"><paragraph> 35.0</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Tremor</paragraph></td><td valign=\"top\"><paragraph> 15.0</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Somnolence</paragraph></td><td valign=\"top\"><paragraph> 5.5</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Dizziness</paragraph></td><td valign=\"top\"><paragraph> 3.5</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Anxiety</paragraph></td><td valign=\"top\"><paragraph> 1.0</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Insomnia</paragraph></td><td valign=\"top\"><paragraph> 1.5</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiovascular</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph> Palpitations</paragraph></td><td valign=\"top\"><paragraph> 5.0</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Tachycardia</paragraph></td><td valign=\"top\"><paragraph> 3.5</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Extrasystoles ventricular</paragraph></td><td valign=\"top\"><paragraph> 1.5</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Vasodilations</paragraph></td><td valign=\"top\"><paragraph> 1.0</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph><content styleCode=\"bold\">Digestive</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph> Nausea</paragraph></td><td valign=\"top\"><paragraph> 3.0</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Dry mouth</paragraph></td><td valign=\"top\"><paragraph> 1.5</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph><content styleCode=\"bold\">Body as a Whole</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph> Headache</paragraph></td><td valign=\"top\"><paragraph> 7.5</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Asthenia</paragraph></td><td valign=\"top\"><paragraph> 2.0</paragraph></td></tr><tr><td colspan=\"2\" valign=\"top\"><paragraph><content styleCode=\"bold\">Skin and Appendages</content></paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> Sweating</paragraph></td><td styleCode=\"Botrule \" valign=\"top\"><paragraph> 1.0</paragraph></td></tr></tbody></table>"],"information_for_patients":["Information for Patients The action of terbutaline sulfate should last up to 6 hours or longer. Terbutaline sulfate should not be used more frequently than recommended. Do not increase the dose or frequency of terbutaline sulfate without consulting your physician. If you find that treatment with terbutaline sulfate becomes less effective for symptomatic relief, your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. While taking terbutaline sulfate, other inhaled drugs and asthma medications should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, tremor or nervousness. If you are pregnant or nursing, contact your physician about use of terbutaline sulfate. Effective and safe use of terbutaline sulfate includes an understanding of the way that it should be administered."],"spl_unclassified_section":["Rx Only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Adults The usual oral dose of terbutaline sulfate for adults is 5 mg administered at approximately six-hour intervals, three times daily, during the hours the patient is usually awake. If side effects are particularly disturbing, the dose may be reduced to 2.5 mg three times daily, and still provide a clinically significant improvement in pulmonary function. The total dose within 24 hours should not exceed 15 mg. Children Terbutaline sulfate is not recommended for use in children below the age of 12 years. A dosage of 2.5 mg three times daily is recommended for children 12-15 years of age. The total dose within 24 hours should not exceed 7.5 mg. If a previously effective dosage regimen fails to provide the usual relief, medical advice should be sought immediately as this is often a sign of seriously worsening asthma that would require reassessment of therapy."],"spl_product_data_elements":["Terbutaline Sulfate Terbutaline Sulfate TERBUTALINE SULFATE TERBUTALINE MICROCRYSTALLINE CELLULOSE LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE, UNSPECIFIED STARCH, CORN T132 Terbutaline Sulfate Terbutaline Sulfate TERBUTALINE SULFATE TERBUTALINE MICROCRYSTALLINE CELLULOSE LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE, UNSPECIFIED STARCH, CORN T;133"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL — 2.5 mg NDC 71205-938-30 TERBUTALINE SULFATE TABLETS, USP 2.5 mg Rx Only 30 TABLETS 71205-938-30","PRINCIPAL DISPLAY PANEL — 5 mg NDC 71205-939-30 TERBUTALINE SULFATE TABLETS, USP 5 mg Rx Only 30 TABLETS 71205-939-30"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year study in Sprague-Dawley rats, terbutaline sulfate caused a significant and dose-related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 50 mg/kg, and above (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m 2 basis). In a 21-month study in CD-1 mice, terbutaline sulfate showed no evidence of tumorigenicity at dietary doses up to 200 mg/kg (approximately 55 times the maximum recommended daily oral dose for adults on a mg/m 2 basis). The mutagenicity potential of terbutaline sulfate has not been determined. Reproduction studies in rats using terbutaline sulfate demonstrated no impairment of fertility at oral doses up to 50 mg/kg (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m 2 basis)."]},"tags":[{"label":"terbutaline","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Beta-2 adrenergic receptor","category":"target"},{"label":"ADRB2","category":"gene"},{"label":"R03AC03","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Oral","category":"route"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Acute exacerbation of asthma","category":"indication"},{"label":"Asthma","category":"indication"},{"label":"Asthma management","category":"indication"},{"label":"Bronchitis","category":"indication"},{"label":"Bronchospasm Prevention","category":"indication"},{"label":"Chronic Obstructive Pulmonary Disease with Bronchospasms","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Agonists","category":"pharmacology"},{"label":"Adrenergic beta-2 Receptor Agonists","category":"pharmacology"},{"label":"Adrenergic beta-Agonists","category":"pharmacology"},{"label":"Anti-Asthmatic Agents","category":"pharmacology"},{"label":"Bronchodilator Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"},{"label":"Sympathomimetics","category":"pharmacology"},{"label":"Tocolytic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING: TOCOLYSIS Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [see Contraindications, Tocolysis . ]"],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"395 reports"},{"date":"","signal":"ASTHMA","source":"FDA FAERS","actionTaken":"350 reports"},{"date":"","signal":"WHEEZING","source":"FDA FAERS","actionTaken":"236 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"184 reports"},{"date":"","signal":"COUGH","source":"FDA FAERS","actionTaken":"181 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"141 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"134 reports"},{"date":"","signal":"LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES","source":"FDA FAERS","actionTaken":"131 reports"},{"date":"","signal":"THERAPEUTIC PRODUCT EFFECT INCOMPLETE","source":"FDA FAERS","actionTaken":"122 reports"},{"date":"","signal":"SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION","source":"FDA FAERS","actionTaken":"104 reports"}],"drugInteractions":[{"drug":"other sympathomimetic agents","severity":"major","mechanism":"combined effect on the cardiovascular system","management":"concomitant use is not recommended; however, aerosol bronchodilators of the adrenergic-stimulant type can be used for acute bronchospasm relief in patients on chronic oral terbutaline sulfate therapy","clinicalEffect":"deleterious to the patient"}],"commonSideEffects":[{"effect":"Tremor","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Nervousness","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Palpitations","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Dizziness","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Headache","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Nausea/vomiting","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Drowsiness","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Tachycardia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Weakness","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Chest discomfort","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Dyspnea","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Sweating","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Pain at injection site","drugRate":"2.0%","severity":"mild","_validated":true},{"effect":"Anxiety","drugRate":"reported","severity":"unknown"},{"effect":"Muscle cramps","drugRate":"reported","severity":"unknown"},{"effect":"Dry mouth","drugRate":"reported","severity":"unknown"},{"effect":"Elevations in liver enzymes","drugRate":"reported","severity":"unknown"},{"effect":"Hypersensitivity vasculitis","drugRate":"reported","severity":"unknown"}],"contraindications":["Oral terbutaline sulfate should not be used for acute or maintenance tocolysis.","Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product."],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies of terbutaline sulfate in pregnant women. Published animal studies show that rat offspring exhibit alterations in behavior and brain development, including decreased cellular proliferation and differentiation when dams were treated subcutaneously with terbutaline during the late stage of pregnancy and lactation period. Terbutaline exposures in rat dams were approximately 6.5 times the common human exposure.","Geriatric use":"In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant diseases and other drug therapy.","Paediatric use":"Terbutaline sulfate is not recommended for patients under the age of 12 years because of insufficient clinical data to establish safety and effectiveness","Hepatic impairment":"or cardiac function and of concomitant diseases and other drug therapy."}},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TERBUTALINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:47:08.680437+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:47:48.296406+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:47:15.783838+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:47:07.315524+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TERBUTALINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:47:16.539187+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:47:05.503734+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:47:40.284032+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: TOCOLYSIS Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmon","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:47:05.503783+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:47:18.078392+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Beta-2 adrenergic receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:47:17.118447+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:47:32.443807+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1315867/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:47:17.017335+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:47:25.514303+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA211832","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:47:05.503792+00:00"}},"allNames":"brethine","offLabel":[],"synonyms":["terbutaline","bricaril","terbutalin","brican","terbutaline sulfate","terbutaline hemisulfate"],"timeline":[{"date":"1974-03-25","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1984-08-17","type":"positive","source":"FDA Orange Book","milestone":"Brethaire approved — 0.2MG/INH"},{"date":"1985-03-19","type":"positive","source":"FDA Orange Book","milestone":"Bricanyl approved — 0.2MG/INH"},{"date":"2004-04-23","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"}],"aiSummary":"Terbutaline (Brethine) is a marketed beta-2 adrenergic agonist used primarily for the prevention and reversal of bronchospasm, competing in a crowded market with other same-class drugs such as salbutamol, isoetarine, pirbuterol, salmeterol, and formoterol. A key strength of Terbutaline is its well-established mechanism of action and long-standing use, supported by a key composition patent expiring in 2028. The primary risk is the strong competition from off-patent alternatives like formoterol, which has 10 generics available, potentially eroding market share.","approvals":[{"date":"1974-03-25","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Brethine","ecosystem":[{"indication":"Acute exacerbation of asthma","otherDrugs":[{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"epinephrine","slug":"epinephrine","company":""},{"name":"levosalbutamol","slug":"levosalbutamol","company":"Oak Pharms Inc"},{"name":"norepinephrine","slug":"norepinephrine","company":"Hospira"}],"globalPrevalence":262000000},{"indication":"Asthma","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"}],"globalPrevalence":262000000},{"indication":"Asthma management","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"budesonide","slug":"budesonide","company":""},{"name":"ciclesonide","slug":"ciclesonide","company":"Takeda Gmbh"}],"globalPrevalence":262000000},{"indication":"Bronchitis","otherDrugs":[{"name":"acetylcysteine","slug":"acetylcysteine","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"cefixime","slug":"cefixime","company":""}],"globalPrevalence":null},{"indication":"Bronchospasm Prevention","otherDrugs":[{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"cromoglicic acid","slug":"cromoglicic-acid","company":"King Pharms"},{"name":"levosalbutamol","slug":"levosalbutamol","company":"Oak Pharms Inc"},{"name":"orciprenaline","slug":"orciprenaline","company":""}],"globalPrevalence":null},{"indication":"Chronic Obstructive Pulmonary Disease with Bronchospasms","otherDrugs":[{"name":"ipratropium","slug":"ipratropium","company":""},{"name":"salbutamol","slug":"salbutamol","company":"Schering"},{"name":"theophylline","slug":"theophylline","company":"Gd Searle Llc"},{"name":"tiotropium bromide","slug":"tiotropium-bromide","company":"Boehringer Ingelheim"}],"globalPrevalence":392000000},{"indication":"Itching of skin","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"allantoin","slug":"allantoin","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Minor Skin Wound Pain","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"allantoin","slug":"allantoin","company":""},{"name":"benzalkonium","slug":"benzalkonium","company":""},{"name":"benzethonium","slug":"benzethonium","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Beta-2 adrenergic receptor","novelty":"First-in-class","targets":[{"gene":"ADRB2","source":"DrugCentral","target":"Beta-2 adrenergic receptor","protein":"Beta-2 adrenergic receptor"}],"modality":"Small Molecule","drugClass":"terbutaline","explanation":"","oneSentence":"","technicalDetail":"Brethine is a selective beta-2 adrenergic receptor agonist that activates the Gs protein-coupled receptor, leading to an increase in intracellular cyclic AMP (cAMP) levels, which in turn causes relaxation of airway smooth muscle cells and bronchodilation."},"commercial":{"launchDate":"1974","_launchSource":"DrugCentral (FDA 1974-03-25, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2598","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TERBUTALINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TERBUTALINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:50:38.858661","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:47:48.297599+00:00","fieldsConflicting":13,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"salbutamol","drugSlug":"salbutamol","fdaApproval":"1981-05-01","relationship":"same-class"},{"drugName":"isoetarine","drugSlug":"isoetarine","fdaApproval":"1979-10-23","relationship":"same-class"},{"drugName":"pirbuterol","drugSlug":"pirbuterol","fdaApproval":"1986-12-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"salmeterol","drugSlug":"salmeterol","fdaApproval":"1994-02-04","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"formoterol","drugSlug":"formoterol","fdaApproval":"2001-02-16","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"clenbuterol","drugSlug":"clenbuterol","fdaApproval":"","relationship":"same-class"},{"drugName":"bitolterol","drugSlug":"bitolterol","fdaApproval":"1984-12-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"indacaterol","drugSlug":"indacaterol","fdaApproval":"2011-07-01","patentExpiry":"Oct 11, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"olodaterol","drugSlug":"olodaterol","fdaApproval":"2014-07-31","patentExpiry":"Jan 19, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"terbutaline","indications":{"approved":[{"id":"terbutaline-prevention-and-reversal-of-bro","name":"Prevention and reversal of bronchospasm","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema","diagnosticRequired":null,"brandNameForIndication":"Brethine"}],"offLabel":[{"name":"Bronchiectasis","source":"DrugCentral","drugName":"TERBUTALINE"},{"name":"Keratoconjunctivitis sicca","source":"DrugCentral","drugName":"TERBUTALINE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Premature labor","source":"DrugCentral","drugName":"TERBUTALINE"}],"pipeline":[]},"currentOwner":"Pharmacare","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"salbutamol","brandName":"salbutamol","genericName":"salbutamol","approvalYear":"1981","relationship":"same-class"},{"drugId":"isoetarine","brandName":"isoetarine","genericName":"isoetarine","approvalYear":"1979","relationship":"same-class"},{"drugId":"pirbuterol","brandName":"pirbuterol","genericName":"pirbuterol","approvalYear":"1986","relationship":"same-class"},{"drugId":"salmeterol","brandName":"salmeterol","genericName":"salmeterol","approvalYear":"1994","relationship":"same-class"},{"drugId":"formoterol","brandName":"formoterol","genericName":"formoterol","approvalYear":"2001","relationship":"same-class"},{"drugId":"clenbuterol","brandName":"clenbuterol","genericName":"clenbuterol","approvalYear":"","relationship":"same-class"},{"drugId":"bitolterol","brandName":"bitolterol","genericName":"bitolterol","approvalYear":"1984","relationship":"same-class"},{"drugId":"indacaterol","brandName":"indacaterol","genericName":"indacaterol","approvalYear":"2011","relationship":"same-class"},{"drugId":"olodaterol","brandName":"olodaterol","genericName":"olodaterol","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04973345","phase":"PHASE2,PHASE3","title":"Terbutaline Sulfate in Adults With Asthma","status":"WITHDRAWN","sponsor":"Kanecia Obie Zimmerman","startDate":"2023-07-07","conditions":["Asthma"],"enrollment":0,"completionDate":"2026-12"},{"nctId":"NCT06097507","phase":"NA","title":"Patient Perspective on Climate Impact of Inhalers","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2023-11-07","conditions":["Asthma"],"enrollment":54,"completionDate":"2024-06-01"},{"nctId":"NCT05193968","phase":"NA","title":"Hot Flashes and Neurovascular Function in Women","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-02-24","conditions":["Hot Flashes","Menopause","Vasomotor System; Labile"],"enrollment":120,"completionDate":"2026-12"},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":["Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome"],"enrollment":5000,"completionDate":"2027-09"},{"nctId":"NCT06626620","phase":"PHASE3","title":"Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2024-01-01","conditions":["Acute Exacerbation of Asthma"],"enrollment":120,"completionDate":"2024-09-30"},{"nctId":"NCT06535087","phase":"","title":"The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","status":"RECRUITING","sponsor":"Wenjing Zhou","startDate":"2024-07-20","conditions":["Pediatric Asthma","Rhinitis, Allergic","Quality of Life"],"enrollment":600,"completionDate":"2027-05-31"},{"nctId":"NCT04527016","phase":"PHASE4","title":"Airway Microbiota Based Treatment of Asthma in Preschool Children","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2021-10-18","conditions":["Asthma in Children"],"enrollment":120,"completionDate":"2024-06-20"},{"nctId":"NCT04433104","phase":"PHASE1,PHASE2","title":"Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2020-06-09","conditions":["COPD"],"enrollment":40,"completionDate":"2022-12-25"},{"nctId":"NCT00802230","phase":"PHASE4","title":"Pharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure","status":"COMPLETED","sponsor":"University of Utah","startDate":"2002-09","conditions":["Heart Failure"],"enrollment":25,"completionDate":"2004-12"},{"nctId":"NCT04705727","phase":"PHASE3","title":"Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation","status":"TERMINATED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2021-08-23","conditions":["Asthma in Children"],"enrollment":102,"completionDate":"2023-06-23"},{"nctId":"NCT05749523","phase":"PHASE4","title":"The Influence of Exercise and Hydration to the Pharmacological Response to Inhaled Terbutalin and Salbutamol in Men","status":"WITHDRAWN","sponsor":"Vibeke Backer","startDate":"2013-11","conditions":["Healthy"],"enrollment":0,"completionDate":"2014-09"},{"nctId":"NCT03219736","phase":"NA","title":"NiPPV in the Treatment of Acute Asthma Exacerbations","status":"WITHDRAWN","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2017-06-01","conditions":["Bronchial Asthma","Status Asthmaticus"],"enrollment":0,"completionDate":"2019-01-01"},{"nctId":"NCT05494307","phase":"PHASE2","title":"The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-09-01","conditions":["Immune Thrombocytopenia"],"enrollment":228,"completionDate":"2024-02-28"},{"nctId":"NCT04468568","phase":"","title":"In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-10-01","conditions":["Myelomeningocele","Terbutaline Adverse Reaction","Pregnancy; Malformation Central Nervous System"],"enrollment":25,"completionDate":"2022-04-01"},{"nctId":"NCT05326269","phase":"NA","title":"Acute Tocolysis With Terbutaline for Suspected Fetal Distress","status":"COMPLETED","sponsor":"Hospital Kemaman","startDate":"2017-04-23","conditions":["Nonreassuring Fetal Status"],"enrollment":100,"completionDate":"2019-09-15"},{"nctId":"NCT03877874","phase":"","title":"The Impact of Anti- Asthmatic Medications on Salivary pH and Dental Caries Pattern in a Group of Egyptian Children With Bronchial Asthma","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2021-07","conditions":["pH"],"enrollment":58,"completionDate":"2021-09"},{"nctId":"NCT03106753","phase":"PHASE4","title":"Success of External Cephalic Version Study","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2017-04-12","conditions":["External Cephalic Version"],"enrollment":34,"completionDate":"2018-05-05"},{"nctId":"NCT04481282","phase":"PHASE2","title":"The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2020-07-08","conditions":["Immune Thrombocytopenia"],"enrollment":40,"completionDate":"2021-07-31"},{"nctId":"NCT03565302","phase":"NA","title":"Beta2-adrenergic Agonism and Muscle Remodelling","status":"UNKNOWN","sponsor":"Morten Hostrup, PhD","startDate":"2018-06-25","conditions":["Hypertrophy","Physiologic Hypertrophy","Physical Activity"],"enrollment":72,"completionDate":"2021-05-30"},{"nctId":"NCT02509299","phase":"NA","title":"Effect of Physiotherapy in Hospitalized COPD Patients","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2019-09-01","conditions":["COPD"],"enrollment":49,"completionDate":"2019-12-14"},{"nctId":"NCT02224157","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-28","conditions":["Asthma"],"enrollment":4215,"completionDate":"2017-08-16"},{"nctId":"NCT02149199","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07-07","conditions":["Asthma"],"enrollment":3850,"completionDate":"2017-08-02"},{"nctId":"NCT04016220","phase":"PHASE1","title":"Nebulized Budesonide Combined With Systemic Corticosteroid in Acute Severe Asthma","status":"UNKNOWN","sponsor":"University of Monastir","startDate":"2019-05-20","conditions":["Acute Asthma"],"enrollment":60,"completionDate":"2020-05-20"},{"nctId":"NCT02515318","phase":"NA","title":"Physiotherapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Universidad de Granada","startDate":"2015-09","conditions":["COPD"],"enrollment":60,"completionDate":"2018-07"},{"nctId":"NCT01944033","phase":"PHASE3","title":"β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2013-07","conditions":["Acute Exacerbation of Chronic Obstructive Airways Disease"],"enrollment":250,"completionDate":"2017-01"},{"nctId":"NCT02557581","phase":"NA","title":"cAMP Signaling and Muscle Adaptations","status":"UNKNOWN","sponsor":"University of Copenhagen","startDate":"2015-07","conditions":["Muscle Hypertrophy in Healthy Young Men"],"enrollment":72,"completionDate":"2017-10"},{"nctId":"NCT01582646","phase":"PHASE2","title":"Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2012-01","conditions":["Postthoracotomy Pain","Postthoracoscopy Neuropathic Pain"],"enrollment":20,"completionDate":"2017-09"},{"nctId":"NCT02115256","phase":"PHASE2,PHASE3","title":"Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline","status":"TERMINATED","sponsor":"Yaakov Beilin","startDate":"2014-07","conditions":["External Cephalic Version"],"enrollment":6,"completionDate":"2015-04"},{"nctId":"NCT02178059","phase":"PHASE1","title":"Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-08","conditions":["Healthy Volunteers"],"enrollment":34,"completionDate":"2014-11"},{"nctId":"NCT02712658","phase":"NA","title":"Role of K+ and Ca2+ in Development of Muscle Fatigue","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2015-09","conditions":["Skeletal Muscle Fatigue in Humans"],"enrollment":10,"completionDate":"2016-03"},{"nctId":"NCT02322788","phase":"PHASE3","title":"Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-03","conditions":["Asthma"],"enrollment":95,"completionDate":"2015-11"},{"nctId":"NCT02790047","phase":"NA","title":"Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-10","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":50,"completionDate":"2018-05"},{"nctId":"NCT00607503","phase":"PHASE1","title":"A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2008-02","conditions":["Type 1 Diabetes"],"enrollment":9,"completionDate":"2008-09"},{"nctId":"NCT02103374","phase":"PHASE4","title":"Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2012-01","conditions":["Severe Chronic Obstructive Pulmonary Disease"],"enrollment":45,"completionDate":"2015-12"},{"nctId":"NCT00214318","phase":"NA","title":"Beta-2 Polymorphisms and Beta Receptor Selectivity","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2005-01","conditions":["Heart Failure"],"enrollment":25,"completionDate":"2007-02"},{"nctId":"NCT02504801","phase":"PHASE4","title":"Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD","status":"UNKNOWN","sponsor":"Xiuyi Zhi","startDate":"2015-07","conditions":["Post Operative Complication, Pulmonary","Lung Cancer","COPD"],"enrollment":73,"completionDate":"2016-10"},{"nctId":"NCT01651962","phase":"PHASE4","title":"Intravenous Terbutaline to Facilitate Labor Epidural Catheter Placement","status":"UNKNOWN","sponsor":"Kai Schoenhage","startDate":"2012-08","conditions":["Labor Pain"],"enrollment":250,"completionDate":"2015-12"},{"nctId":"NCT01081002","phase":"PHASE4","title":"Propofol Sedation During Upper Endoscopy With and Without Topical Pharyngeal Anesthesia","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2009-08","conditions":["Conscious Sedation"],"enrollment":294,"completionDate":"2010-05"},{"nctId":"NCT00849095","phase":"PHASE3","title":"Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2009-04","conditions":["Asthma"],"enrollment":860,"completionDate":"2013-05"},{"nctId":"NCT00974051","phase":"NA","title":"Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-03","conditions":["Type 1 Diabetes"],"enrollment":16,"completionDate":"2008-12"},{"nctId":"NCT00124995","phase":"PHASE4","title":"Trial of Terbutaline for the Treatment of Status Asthmaticus in Children","status":"COMPLETED","sponsor":"Connecticut Children's Medical Center","startDate":"2003-10","conditions":["Status Asthmaticus"],"enrollment":40,"completionDate":"2006-10"},{"nctId":"NCT00839800","phase":"PHASE3","title":"Study to Investigate the Efficacy of Symbicort® SMART.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":["Asthma"],"enrollment":2091,"completionDate":"2011-02"},{"nctId":"NCT01096017","phase":"PHASE3","title":"To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-03","conditions":["Asthma"],"enrollment":24,"completionDate":"2010-04"},{"nctId":"NCT00837967","phase":"PHASE3","title":"Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-01","conditions":["Asthma"],"enrollment":25,"completionDate":"2009-07"},{"nctId":"NCT00628758","phase":"PHASE3","title":"A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":["Asthma"],"enrollment":430,"completionDate":"2008-09"},{"nctId":"NCT00989833","phase":"PHASE2","title":"Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":["Exercise Induced Asthma"],"enrollment":66,"completionDate":"2010-07"},{"nctId":"NCT00518141","phase":"NA","title":"Use of Acetyl Salicylic Acid and Terbutalin in Assisted Reproductive Techniques (ART)","status":"COMPLETED","sponsor":"Sykehuset Telemark","startDate":"2006-03","conditions":["Reproductive Techniques, Assisted"],"enrollment":300,"completionDate":"2009-05"},{"nctId":"NCT00567476","phase":"PHASE4","title":"Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":["Asthma"],"enrollment":116,"completionDate":"2010-04"},{"nctId":"NCT00531791","phase":"PHASE3","title":"Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation","status":"COMPLETED","sponsor":"Laval University","startDate":"2007-11","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":14,"completionDate":"2009-09"},{"nctId":"NCT00185887","phase":"NA","title":"Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation","status":"COMPLETED","sponsor":"Stanford University","startDate":"2003-10","conditions":["Fetal Distress"],"enrollment":110,"completionDate":"2007-10"},{"nctId":"NCT00244608","phase":"PHASE3","title":"A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":["Asthma"],"enrollment":100,"completionDate":"2007-03"},{"nctId":"NCT00326053","phase":"PHASE3","title":"Prevention of Asthma Relapse After Discharge From Emergency","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":["Asthma"],"enrollment":600,"completionDate":"2007-05"},{"nctId":"NCT00242775","phase":"PHASE3","title":"Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":["Asthma"],"enrollment":2100,"completionDate":"2006-05"},{"nctId":"NCT00259766","phase":"PHASE3","title":"SHARE - Symbicort and Health Economics in a Real Life Evaluation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-04","conditions":["Asthma"],"enrollment":1970,"completionDate":"2007-05"},{"nctId":"NCT01136421","phase":"PHASE3","title":"Magnesium Sulfate Versus Ipratropuim Bromide in Acute Exacerbation of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2005-01","conditions":["COPD Exacerbation"],"enrollment":124,"completionDate":"2007-06"},{"nctId":"NCT00668408","phase":"PHASE4","title":"LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2008-05","conditions":["Lung Diseases, Obstructive","Chronic Heart Failure","Chronic Hypoxemia"],"enrollment":1000,"completionDate":"2012-10"},{"nctId":"NCT00914797","phase":"PHASE4","title":"Terbutaline Concentrations in Blood and Urine","status":"UNKNOWN","sponsor":"Bispebjerg Hospital","startDate":"2009-07","conditions":["Asthma"],"enrollment":30,"completionDate":"2010-03"},{"nctId":"NCT00421122","phase":"PHASE3","title":"Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":315,"completionDate":"2007-11"},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":["Asthma"],"enrollment":1600,"completionDate":"2006-05"},{"nctId":"NCT00750568","phase":"","title":"Intravenous Terbutaline in Severe Status Asthmaticus","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2007-10","conditions":["Status Asthmaticus"],"enrollment":36,"completionDate":"2009-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection, Tablet","formulations":[{"form":"INJECTION","route":"SUBCUTANEOUS","productName":"Terbutaline Sulfate"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Terbutaline Sulfate"},{"form":"TABLET","route":"ORAL","productName":"TERBUTALINE SULFATE"},{"form":"TABLET","route":"ORAL","productName":"Terbutaline Sulfate"},{"form":"TABLET","route":"ORAL","productName":"Terbutaline Sulfate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148026","MMSL":"41721","NDDF":"001812","UNII":"N8ONU3L3PG","VUID":"4019941","CHEBI":"CHEBI:9449","VANDF":"4018396","INN_ID":"2616","RXNORM":"10368","UMLSCUI":"C0039542","chemblId":"CHEMBL1315867","ChEMBL_ID":"CHEMBL1760","KEGG_DRUG":"D00688","DRUGBANK_ID":"DB00871","PUBCHEM_CID":"5403","SNOMEDCT_US":"24583009","IUPHAR_LIGAND_ID":"560","SECONDARY_CAS_RN":"23031-32-5","MESH_DESCRIPTOR_UI":"D013726"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Pharmacare","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"15.0 hours","clearance":"3.4 mL/min/kg","bioavailability":"14%","fractionUnbound":"0.75%","volumeOfDistribution":"1.5 L/kg"},"publicationCount":3565,"therapeuticAreas":["Respiratory"],"atcClassification":{"source":"DrugCentral","atcCode":"R03AC03","allCodes":["R03AC03","R03CC03","R03CC53"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":9,"_genericFilersChecked":true,"genericManufacturerList":["Areva Pharms","Chartwell Injectable","Dr Reddys","Epic Pharma Llc","Fresenius Kabi Usa","Hikma Farmaceutica","Impax Labs","Lannett Co Inc","Twi Pharms"],"status":"approved","companyName":"Pharmacare","companyId":"","modality":"Small molecule","firstApprovalDate":"1974","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1974-03-25T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1979-05-24T00:00:00.000Z","mah":"ANI PHARMS","brand_name_local":null,"application_number":"NDA017849"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-05-26T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA076887"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-04-08T00:00:00.000Z","mah":"IMPAX LABS","brand_name_local":null,"application_number":"ANDA075877"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-04-08T00:00:00.000Z","mah":"HIKMA FARMACEUTICA","brand_name_local":null,"application_number":"ANDA078630"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-06-19T00:00:00.000Z","mah":"TWI PHARMS","brand_name_local":null,"application_number":"ANDA211832"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:47:48.297599+00:00","fieldsConflicting":13,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}